ATEM Capital

Franceatemcap.com

ATEM Capital is a venture capital firm based in France, investing in Healthcare & Life Sciences, Industry & Hardware and Biotechnology, 9 tracked investments.

View Full Profile Website

Investments Tracked

See full portfolio →

About ATEM Capital

Operating out of France, ATEM Capital is a venture capital firm. Our dataset covers 9 investments involving ATEM Capital.

Recorded deals span Healthcare & Life Sciences, Industry & Hardware, Biotechnology and Liver Disease. Coverage extends to 8 sectors in total. Participation spans Series A and Series B rounds.

Investment Focus

Stage Focus

series-aseries-b

Sectors

Healthcare & Life SciencesIndustry & Hardwarebiotechnologyliver diseaseNASHoncologypharmaceutical-developmentpharmaceuticals

ATEM Capital Portfolio Companies

8 tracked holdings.

Full portfolio →

Amolyt PharmaFrance Arpeggio BiosciencesUnited States IridiaUnited States Deka Biosciences Tobira TherapeuticsUnited States Walden BiosciencesUnited States Syndax PharmaceuticalsUnited States Pria CareUnited States

Portfolio outcomes

6 active3 acquired25.0% exit rate

Team

Allan GobbsManaging Partner

Managing Partner at ATEM Capital. Five portfolio companies went public on NASDAQ including Atea Pharmaceuticals and Syndax Pharmaceuticals. Four portfolio companies acquired including Tobira Therapeutics for $1.7B and Amolyt Pharmaceuticals…

Elena MaleyManaging Partner

Managing Partner at ATEM Capital with over ten years of venture capital and private equity experience. Partner at investment firm managing US$0.75B partnership. Board member of Syndax Pharmaceuticals.

Zakhar LeikinMedical Advisor

Medical Advisor at ATEM Capital and Chief Medical Director at NovaMedica. Over 15 years in clinical trials, drug development, and investments. Former practicing neurosurgeon and cardiothoracic surgeon.

Ilia ArdabevskiiPrincipal

Principal at ATEM Capital with over 5 years in finance and investment. Created executive summaries on 50+ life sciences companies and participated in due diligence for $30M in investment deals.

Ilya YasnyManaging Partner

Dmitry KobyzevManaging Partner

Joseph CamardoAdvisory Board

30 years of global biopharmaceutical experience with extensive oncology drug development expertise. Head of Medical Affairs at ADC Therapeutics. Former SVP at Celgene Global Health.

Bruce BurlingtonAdvisory Board

Ed GodberAdvisory Board

Rivka KreitmanAdvisory Board

Roberto PellicciariAdvisory Board

Viktor KotelianskyAdvisory Board